



ALPHA COGNITION INC.

Consolidated Financial Statements

(Expressed in United States Dollars)

For the Three Months Ended March 31, 2021 and 2020

ALPHA COGNITION INC.
TABLE OF CONTENTS
(Expressed in United States Dollars)

	PAGE
NOTICE TO READERS	2
FINANCIAL STATEMENTS	
Consolidated Statements of Financial Position	3
Consolidated Statements of Loss and Comprehensive Loss	4
Consolidated Statements of Changes in Changes in Equity (Deficiency).....	5
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8

**NOTICE OF NO AUDITOR REVIEW OF
CONDENSED INTERIM FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements have been prepared by and are the responsibility of management.

The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of condensed interim financial statements by an entity's auditor.

ALPHA COGNITION INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Expressed in United States Dollars)

	Note	March 31, 2021	December 31, 2020
		\$	\$
ASSETS			
Current assets			
Cash		7,238,038	5,926,350
Subscription receipts receivable	8	-	1,439,223
Other receivable		2,438	-
Tax recoverable		19,731	19,943
Prepaid expenses and other current assets		180,044	314,715
		7,440,251	7,700,231
Equipment		6,985	6,837
Intangible asset, net	4	782,142	729,137
		8,229,378	8,436,205
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities	5	614,029	203,853
Related parties payable	7,10	4,940	11,542
Refundable subscription receipts	8	-	3,337,963
Promissory note - current portion	7	24,000	24,000
		642,969	3,577,358
Convertible debentures, net	6	-	2,257,109
Promissory note	7	961,460	933,899
Derivative liability	6,8	7,923,603	1,651,831
		9,528,032	8,420,197
SHAREHOLDERS' DEFICIENCY			
Share capital	8	24,655,015	14,568,312
Reserves	8	4,770,513	3,936,583
Accumulated other comprehensive income		(10,347)	-
Accumulated deficit		(30,713,835)	(18,488,887)
		(1,298,654)	16,008
		8,229,378	8,436,205

Note 11 – Commitments

Approved on behalf of the Board on May 28, 2021

_____/s/ Kenneth Cawkell_____, Director

_____/s/ Len Mertz_____, Director

The accompanying notes are an integral part of these consolidated financial statements.

ALPHA COGNITION INC.
CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Expressed in United States Dollars)

		For the three months ended	
	Note	March 31,	
		2021	2020
		\$	\$
Operating expenses			
Accretion expenses	6,7	404,194	24,286
Amortization expense	4	20,594	19,761
Depreciation		331	-
Interest	6,7	12,002	6,371
Management Fees	10	108,801	54,000
Other general and administrative	10	52,859	23,108
Professional fees	10	81,625	29,455
Registrar and filing fees		8,034	-
Research and development	9	1,622,178	826,391
Share-based compensation	8	145,447	68,111
		2,456,065	1,051,483
Loss before other items		(2,456,065)	(1,051,483)
Other items			
Foreign exchange gain (loss)		18,149	(1,652)
Interest income		1,319	17,930
Business investigation costs	3	(37,504)	-
Listing expense	3	(1,851,194)	-
Loss on revaluation of derivative liability	6,8	(7,899,653)	-
		(9,768,883)	16,278
Net loss and comprehensive loss		(12,224,948)	(1,035,205)
Basic and diluted net loss per share		(0.28)	(0.02)
Basic and diluted weighted average number of shares outstanding		44,372,787	42,896,524

The accompanying notes are an integral part of these consolidated financial statements.

ALPHA COGNITION INC.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)
(Expressed in United States Dollars)

	Class A		Class B		Preferred shares		Total share capital		Reserves	Other Comprehensive Income	Accumulated Deficit	Total		
	Common shares		Restricted shares		Common shares		Preferred shares							
	Number	Amount	Number	Amount	Number	Amount	Number	Amount						
		\$		\$		\$		\$	\$	\$	\$	\$		
Balance, December 31, 2019	40,416,190	14,336,137	-	-	2,480,334	115,376	7,916,380	62	50,812,904	14,451,575	3,532,914	-	(12,740,194)	5,244,295
Stock-based compensation	-	-	-	-	-	-	-	-	-	-	276,618	-	-	276,618
Loss for the period	-	-	-	-	-	-	-	-	-	-	-	-	(1,035,205)	(1,035,205)
Balance, March 31, 2020	40,416,190	14,336,137	-	-	2,480,334	115,376	7,916,380	62	50,812,904	14,451,575	3,809,532	-	(13,775,399)	4,485,708
Share conversion	2,480,334	115,376	-	-	(2,480,334)	(115,376)	-	-	-	-	-	-	-	-
Options exercised	100,000	116,737	-	-	-	-	-	-	100,000	116,737	(115,737)	-	-	1,000
Share-based compensation	-	-	-	-	-	-	-	-	-	-	278,302	-	-	278,302
Forfeited share options	-	-	-	-	-	-	-	-	-	-	(35,514)	-	35,514	-
Loss for the period	-	-	-	-	-	-	-	-	-	-	-	-	(4,749,002)	(4,749,002)
Balance, December 31, 2020	42,996,524	14,568,250	-	-	-	-	7,916,380	62	50,912,904	14,568,312	3,936,583	-	(18,488,887)	16,008

ALPHA COGNITION INC.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)
(Expressed in United States Dollars)

	Class A		Class B		Total share capital		Reserves	Other Compre- hensive Income	Accumulated Deficit	Total				
	Common shares		Restricted shares		Common shares						Preferred shares			
	Number	Amount	Number	Amount	Number	Amount					Number	Amount		
Balance, December 31, 2020	42,996,524	14,568,250	-	-	-	-	7,916,380	62	50,912,904	14,568,312	3,936,583	-	(18,488,887)	16,008
Shares issued for cash	2,771,749	3,410,977	-	-	-	-	-	-	2,771,749	3,410,977	-	-	-	3,410,977
Shares issued for conversion of convertible promissory notes and interest	2,234,036	1,971,133	-	-	-	-	-	-	2,234,036	1,971,133	-	-	-	1,971,133
Units issued for conversion of convertible promissory notes and interest	1,613,186	2,296,019	-	-	-	-	-	-	1,613,186	2,296,019	-	-	-	2,296,019
Eliminate capital stock of Alpha Cognition Canada Inc.	(49,615,495)	-	-	-	-	-	(7,916,380)	-	(57,531,875)	-	-	-	-	-
Opening balance of Alpha Cognition Inc.	1,640,057	-	-	-	-	-	-	-	1,640,057	-	-	-	-	-
Issuance of shares to former shareholders of ACI Canada	42,615,495	1,560,239	7,000,000	256,285	-	-	7,916,380	289,834	57,531,875	2,106,358	88,470	-	-	2,194,828
Reallocation of ACI Canada's common shares book value	-	(3,138,629)	-	3,138,629	-	-	-	-	-	-	-	-	-	-
Shares issued for cash	588,375	755,662	-	-	-	-	-	-	588,375	755,662	-	-	-	755,662
Share issuance costs	-	(453,446)	-	-	-	-	-	-	-	(453,446)	101,662	-	-	(351,784)
Share-based compensation	-	-	-	-	-	-	-	-	-	-	643,798	-	-	643,798
Foreign exchange on translation	-	-	-	-	-	-	-	-	-	-	-	(10,347)	-	(10,347)
Loss for the period	-	-	-	-	-	-	-	-	-	-	-	-	(12,224,948)	(12,224,948)
Balance, March 31, 2021	44,843,927	20,970,205	7,000,000	3,394,914	-	-	7,916,380	289,896	59,760,307	24,655,015	4,770,513	(10,347)	(30,713,835)	(1,298,654)

The accompanying notes are an integral part of these consolidated financial statements.

ALPHA COGNITION INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in United States Dollars)

	For the three months ended	
	March 31,	
	2021	2020
	\$	\$
Cash flows used in operating activities		
Loss for the period	(12,224,948)	(1,035,205)
Adjustments for non-cash items		
Amortization of intangible assets	20,594	19,761
Accretion of discount on convertible promissory notes	376,633	-
Accretion of discount on promissory note	27,561	24,286
Accrued interest	11,503	5,974
Depreciation of equipment	331	-
Listing expense	1,851,194	-
Loss on revaluation of derivative liability	7,899,653	-
Share-based compensation	643,798	276,618
	(1,393,681)	(708,566)
Changes in non-cash operating working capital items:		
Other receivables	(2,438)	-
Tax recoverable	212	(12,321)
Prepaid expenses and other current assets	140,377	(398,026)
Accounts payable and accrued liabilities	222,547	48,337
Corporate tax payable	-	802
Related parties payable	(4,060)	(35,524)
	(1,037,043)	(1,105,298)
Cash flows provided by investing activities		
Cash acquired in RTO	523,041	-
Acquisition of intangible assets	(73,599)	-
Acquisition of equipment	(479)	-
	448,963	-
Cash flows provided by (used in) financing activities		
Shares issued for cash	2,267,899	-
Interest paid on loans payable	(6,000)	(4,000)
Share issuance costs	(351,784)	-
	1,910,115	(4,000)
Effect of foreign exchange on cash	(10,347)	-
Change in cash during the period	1,311,688	(1,109,298)
Cash, beginning of period	5,926,350	5,497,508
Cash, end of period	7,238,038	4,388,210

Note 14 – Supplemental disclosure with respect to cash flows

The accompanying notes are an integral part of these consolidated financial statements.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 1 – NATURE AND CONTINUANCE OF OPERATIONS

Alpha Cognition Inc. (“ACI” or the “Company”), formerly Crystal Bridge Enterprises Inc., is the parent company of Alpha Cognition Canada Inc. (“ACI Canada”), formerly Alpha Cognition Inc. The Company operates from its three offices located in Charlottetown, Prince Edward Island; Vancouver, British Columbia; and West Palm Beach, Florida and is in the business of researching and developing pharmaceutical treatments for neurological diseases. The head office and registered and records office of the Company is 439 Helmcken Street, Vancouver, BC, V6B 2E6. The Company’s common shares trade on the TSX Venture Exchange (“TSX-V”) under the trading symbol “ACOG”.

On March 18, 2021, the Company announced the successful closing of its Qualifying Transaction with ACI Canada (the "Transaction" as defined in Note 3). Pursuant to the Transaction, ACI Canada was acquired by and became a wholly-owned subsidiary of ACI. As part of the Transaction, on March 18, 2021, ACI changed its name to Alpha Cognition Inc. and ACI Canada changed its name to Alpha Cognition Canada Inc. At the time of completion of the Transaction, ACI had 59,171,932 shares issued and outstanding which included 57,531,875 common shares issued to former ACI Canada shareholders, representing 97.23% of the Company’s issued and outstanding shares. Initially, the common shares of the Company issued in connection with the Transaction were listed on TSX-V under the ticker symbol “CRYS”. Effective March 30, 2021, the trading symbol of ACI was changed to “ACOG”.

Upon closing of the Transaction, the shareholders of ACI Canada owned 97.23% of the shares of the Company, and as a result, the transaction is considered a reverse acquisition of the Company by ACI Canada. All previous common shares, share options, and warrants were exchanged at a ratio of one share of ACI Canada for one of ACI. For accounting purposes, ACI Canada is considered the acquirer and the Company, the acquiree. Accordingly, the consolidated financial statements are in the name of Alpha Cognition Inc.; however, they are a continuation of the financial statements of ACI Canada (Note 3).

On March 18, 2021, immediately before the Transaction, the Company completed a share consolidation on the basis of one new post-consolidation common share for every 7.14 pre-consolidation common shares. All current and comparative references to the number of common shares, weighted average number of common shares, loss per share, stock options and warrants have been restated to give effect to this share consolidation.

These condensed interim consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The Company has not generated revenues from its operations to date and as at March 31, 2021, had a deficit of \$30,713,835 (December 31, 2020 - \$18,488,887) which has been primarily financed by equity. The Company’s continuing operations, as intended, are dependent upon its ability to generate cash flows or obtain additional financing. Management is of the opinion that it does have sufficient working capital to meet the Company’s liabilities and commitments as they become due for the upcoming 12 months. There is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company.

These condensed interim consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern assumption was not appropriate for these condensed interim financial statements, adjustments would be necessary to the statement of financial position classifications used. Such adjustments could be material.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. The Company’s operations have not been drastically impacted by the pandemic. Management of the Company continues to monitor the situation and is following the protocols and rules set in place by the provincial, state, and federal governments.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of the significant accounting policies used in the preparation of these consolidated financial statements.

Statement of compliance

These condensed interim consolidated financial statements, including comparatives, have been prepared in accordance with International Accounts Standards (“IAS”) 34, “Condensed Interim Financial Reporting” using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”).

This condensed interim financial report does not include all of the information required of a full annual financial report and is intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that this financial report be read in conjunction with the audited financial statements of Alpha Cognition Canada Inc. for the year ended December 31, 2020.

Basis of presentation

The condensed interim consolidated financial statements of the Company have been prepared on an accrual basis and are based on historical costs, except for certain financial assets and liabilities, including derivative instruments that are measured at fair value. The condensed interim consolidated financial statements are presented in United States dollars unless otherwise noted.

Basis of consolidation

These condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries at the end of the reporting period as follows:

	Incorporation	Percentage owned	
		2021	2020
Alpha Cognition Canada Inc. (“ACI Canada”)	Canada	100%	-
Companies owned by ACI Canada:			
Alpha Cognition USA Inc. (“ACI USA”)	USA	100%	100%

All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated upon consolidation.

Functional and presentation currency

The condensed interim consolidated financial statements are presented in United States dollars (“USD”) unless otherwise noted. The functional currency of an entity is the currency of the primary economic environment in which the entity operates. The functional currency of the Company is Canadian dollars (“CAD”) and its subsidiaries are USD. The functional currency determinations were conducted through an analysis of the consideration factors identified in IAS 21, *The Effects of Changes in Foreign Exchange Rates*.

Transactions in currencies other than USD are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities in foreign currencies are translated at historical rates. Revenues and expenses are translated at the average exchange rates approximating those in effect during the reporting period.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (continued)

Functional and presentation currency (continued)

For the purposes of presenting condensed interim consolidated financial statements, the assets and liabilities of the Company's CAD operations are translated to USD at the exchange rate at the reporting date. The income and expenses are translated using average rate. Foreign currency differences that arise on translation for consolidation purposes are recognized in other comprehensive income (loss).

Significant accounting estimates and judgments

The preparation of the condensed interim consolidated financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported revenues and expenses during the period.

Although management uses historical experience and its best knowledge of the amount, events or actions to form the basis for judgments and estimates, actual results may differ from these estimates.

Critical judgments exercised in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are as follows:

Functional currency

Management is required to assess the functional currency of each entity of the Company. In concluding on the functional currencies of the parent and its subsidiaries, management considered the currency that mainly influences the sale prices of goods and services and the cost of providing goods and services in each jurisdiction in which the Company operates. When no single currency was clearly dominant the Company also considered secondary indicators including the currency in which funds from financing activities are denominated and the currency in which funds are retained. As at March 31, 2021, the functional currency of the Company is CAD and its subsidiaries is the USD.

Income taxes

In assessing the probability of realizing income tax assets, management makes estimates related to expectation of future taxable income, applicable tax opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified.

Going concern

The assessment of the Company's ability to continue as a going concern involves management judgement about the Company's resources and future prospects.

Impairment of intangible assets

The application of the Company's accounting policy for intangible assets requires judgment in determining whether it is likely that future economic benefits will flow to the Company, which may be based on assumptions about future events or circumstances. Estimates and assumptions may change if new information becomes available. If, after expenditures are capitalized, information becomes available suggesting that the recovery of expenditures is unlikely, the amount capitalized is written off in profit or loss in the period the new information becomes available.

Information about assumptions and estimation uncertainties that have a risk of resulting in significant adjustments are as follows:

Share-based payment transactions and valuation of derivative liability

The Company uses the Black-Scholes Option Pricing Model to determine the fair value of stock options, standalone share purchase warrants issued and derivative liability. This model requires the input of subjective assumptions including expected share price volatility, interest rate, and forfeiture rate. Changes in the input assumptions can materially affect the fair value estimate and the Company's earnings (loss) and equity reserves.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (continued)

Significant accounting estimates and judgments (continued)

Useful lives of intangible assets

The Company records intangible assets acquired at their fair value. Determining fair value requires management to use estimates that could be material. Following initial recognition, the Company carries the value of intangible assets at cost less accumulated amortization and any accumulated impairment losses. Amortization is recorded on a straight-line basis based upon management's estimate of the useful life and residual value. The estimates are reviewed at least annually and are updated if expectations change as a result of technical obsolescence or legal and other limits to use.

Equipment

Equipment is stated at historical cost less accumulated depreciation and accumulated impairment losses.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in profit or loss.

Amortization is charged over the estimated useful lives using the declining balance method as follows:

Computer equipment	55%
Other equipment	20%

Intangible assets

The Company has intangible assets as outlined below. Intangible assets are carried at cost less accumulated amortization and any impairment losses. The amortization method, useful life and residual values are assessed annually. Amortization expense is recorded on a straight-line basis beginning with the month the corresponding assets are available for use and over the estimated useful lives provided below:

Licenses	15 years
Trademarks	10 years

If, after expenditures are capitalized, events or changes in circumstances indicate that the carrying amount may not be recoverable, the amount capitalized is written off in profit or loss in the period the new information becomes available.

Upon retirement or disposal, the cost of the asset disposed of and the related accumulated amortization are removed from the accounts and any gain or loss is reflected in profit and loss.

Accounting pronouncements not yet adopted

A number of amendments to standards and interpretations applicable to the Company are not yet effective for the three months ended March 31, 2021, and have not been applied in preparing these condensed interim consolidated financial statements nor does the Company expect these amendments to have a significant effect on its condensed interim consolidated financial statements.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 3 – REVERSE ACQUISITION

On October 27, 2020, ACI Canada entered into an Arrangement Agreement with ACI whereby ACI would acquire 100% of the issued and outstanding shares of ACI Canada by issuing to the shareholders of ACI Canada one common share of ACI ("CPC Share") for every one common share of ACI Canada share held by each ACI Canada shareholder (the "Transaction"). Certain US resident ACI Canada shareholders agreed to receive a restricted voting share (a "Restricted Voting Share") in place of a CPC Share which is equivalent to a CPC Share except that it will not be counted in a shareholder vote for the election of directors. In addition, holders of Class C Preferred shares of ACI Canada received one Class B Preferred Share of ACI for each Class C Preferred share of ACI Canada held by such shareholder. The outstanding options and warrants of ACI Canada became convertible into options and warrants of ACI.

On March 18, 2021, the Transaction completed resulting in ACI acquiring 100% of the shares of ACI Canada and ACI Canada's shareholders receiving 42,615,495 post-consolidated common shares, 7,000,000 restricted voting shares, 7,916,380 preferred shares, 11,819,169 warrants, and 10,069,365 share options of ACI. The ACI shareholders retained 1,604,507 common shares on completion of the transaction and the former ACI share option holders were granted 108,543 share options.

The transaction constitutes a reverse acquisition of ACI and has been accounted for as a reverse acquisition transaction in accordance with the guidance provided under IFRS 2, *Share-based Payment* and IFRS 3, *Business Combinations*. As ACI did not qualify as a business according to the definition in IFRS 3, *Business Combination*, this reverse acquisition does not constitute a business combination; rather the transaction was accounted for as an asset acquisition by the issuance of shares of the Company, for the net assets of ACI and its public listing. Accordingly, the transaction has been accounted for at the fair value of the equity instruments granted by the shareholders of ACI Canada to the shareholders and option holders of ACI. The sum of the fair value of the consideration paid (based on the fair value of the ACI shares just prior to the reverse acquisition) less the ACI net assets acquired, has been recognized as a listing expense in profit or loss for the three month period ended March 31, 2021.

For accounting purposes, ACI Canada was treated as the accounting parent company (legal subsidiary) and ACI has been treated as the accounting subsidiary (legal parent) in these condensed interim consolidated financial statements. As ACI Canada was deemed to be the acquirer for accounting purposes, its assets, liabilities and operations since incorporation are included in these condensed interim consolidated financial statements at their historical carrying value. The results of operations of ACI are included in these condensed interim consolidated financial statements from the date of the reverse acquisition of March 18, 2021.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 3 – REVERSE ACQUISITION (continued)

The following represents management's estimate of the fair value of the ACI net assets acquired as at March 18, 2021 as a result of the reverse acquisition and is subject to final valuation adjustments.

	Total
	\$
Cost of acquisition:	
Shares retained by public company shareholders	
- 1,640,057 shares at CAD \$1.60 x 0.8027	2,106,358
Fair value of stock options	88,470
	2,194,828
Allocated as follows:	
Cash	523,041
Prepaid expenses	5,706
Liabilities	(185,113)
	343,634
Allocated to listing expense	1,851,194
	2,194,828

Share options granted were valued using the Black Scholes model using the following weighted average assumptions: risk free rate of 0.23%, volatility of 123%, dividend yield of \$nil, and expected lives of 1.85 years.

During the three months ended March 31, 2021, the Company incurred costs of \$37,504 (three months ended March 31, 2020 - \$nil) related to the reverse acquisition that were recorded as business investigation costs.

NOTE 4 – INTANGIBLE ASSET

	Licenses	Trademark	Total
	\$		
Cost:			
At December 31, 2019 and 2020	1,185,633	-	1,185,633
Additions	50,000	23,599	73,599
At March 31, 2021	1,235,633	23,599	1,259,232
Amortization:			
At December 31, 2019	377,453	-	377,453
Additions	79,043	-	79,043
At December 31, 2020	456,496	-	456,496
Additions	20,594	-	20,594
At March 31, 2021	477,090	-	477,090
Net book value:			
At December 31, 2020	729,137	-	729,137
At March 31, 2021	758,543	23,599	782,142

During the three months ended March 31, 2021, the Company paid \$23,599 (CAD \$30,000) for the assignment of a Canadian Trademark Application which became effective April 1, 2021, as such, no amortization has been recorded during the period.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	March 31, 2021	December 31, 2020
	\$	\$
Accounts payable	424,347	27,542
Accrued liabilities	178,432	166,415
Salaries payable	11,250	9,896
	614,029	203,853

NOTE 6 – CONVERTIBLE DEBENTURES AND DERIVATIVE LIABILITY

	Convertible Debentures	Derivative liability	Total
	\$	\$	\$
Balance, December 31, 2019	-	-	-
Proceeds	4,000,000	-	4,000,000
Allocation of proceeds to derivative liability	(2,386,175)	2,386,175	-
Accretion	558,078	-	558,078
Accrued interest	85,206	-	85,206
Revaluation of derivative liability	-	(734,344)	(734,344)
Balance, December 31, 2020	2,257,109	1,651,831	3,908,940
Accretion	376,633	-	376,633
Accrued interest	5,529	-	5,529
Revaluation of derivative liability	-	(23,950)	(23,950)
Conversion	(2,639,271)	(1,627,881)	(4,267,152)
Balance, March 31, 2021	-	-	-

On April 27, 2020, the Company received \$212,299 from various third party lenders and \$1,787,701 from various directors and officers of the Company for the issuance of convertible debentures (“First Note”) bearing interest at 5% per annum, minimum six months interest guaranteed, and expiring on October 27, 2021, and one warrant (“First Note Warrant”) giving the lender the right to purchase a second convertible promissory note (“Second Note”) having the same terms as the First Note, upon payment equal to the principal amount of the First Note and expiring October 30, 2020. At the option of the lender, the lender can convert their promissory note and any accrued interest into Common shares of the Company, for a price equal to the lower of 20% discount to the per share price of a Value Transaction, being any transaction which has the effect directly or indirectly of valuing the Company, its assets or undertaking including but not limited to a merger or acquisition, a private placement of the Company, issuance of convertible debentures, an initial public offering (“IPO”), a reverse take-over or merger (“RTO”), or a valuation report completed by an independent banker or certified business valuator, or \$1.60. In the event the convertible promissory notes remain outstanding at October 27, 2021, the promissory notes will automatically convert into Common shares of the Company at \$1.28 per Common share.

As the conversion price of the promissory notes varies depending on certain factors, the Company recorded an embedded derivative liability on its consolidated statements of financial position with a corresponding debt discount which is netted against the principal amount of the convertible debentures. The Company accretes the debt discount associated with the embedded derivative liability to accretion expense over the term of the convertible debentures using the effective interest rate method. The embedded derivative liability is initially measured at fair value and re-measured at the end of each reporting period with any changes in fair value reported in profit and loss.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 6 – CONVERTIBLE DEBENTURES AND DERIVATIVE LIABILITY (continued)

In October 2020, the Company offered the holders of the First Note Warrants the option to purchase Subscription Receipts (defined in Note 8) at a 20% discount through the exercising of their warrants, conditional on the closing of the Transaction. If the Transaction terminated or did not complete by December 31, 2020 or such later date as agreed to by ACI Canada and ACI, the holders would receive the Second Note. The Company received \$2,000,000 for the exercise of the First Note Warrants of which \$59,319 was received for a Second Note and \$1,940,681 was received for the elected Subscription Receipts. In March 2021, the Transaction closed and all First Note Warrant holders were issued Subscription Receipts.

The initial fair value of the embedded derivative for the First Note and warrant was determined to be \$1,253,963 using the Black- Scholes Option Pricing model with the following assumptions:

Risk-free interest rate	0.15% - 0.24%
Dividend yield	-
Expected life	0.43-1.5 years
Volatility	139%
Probability of automatic conversion	25%
Probability of conversion at \$1.60 per share	25%
Probability of conversion at a 20% discount to the per share price of a Funding Transaction	50%

The initial fair value of the embedded derivative for the Second Note was determined to be \$1,132,212 using the Black-Scholes Option Pricing model with the following assumptions:

Risk-free interest rate	0.09% - 0.13%
Dividend yield	-
Expected life	0.25-2.08 years
Volatility	122% - 173%
Probability of automatic conversion	2.5%
Probability of conversion at \$1.60 per share	2.5%
Probability of conversion at a 20% discount to the per share price of a Funding Transaction	95%

As of December 31, 2020, the fair value of the embedded derivative for the First Note and Second Note was determined to be \$1,651,831 using the Black- Scholes Option Pricing model with the following assumptions:

Risk-free interest rate	0.08% - 0.13%
Dividend yield	-
Expected life	0.33-2.13 years
Volatility	90% - 141%
Probability of automatic conversion	2.5%
Probability of conversion at \$1.60 per share	2.5%
Probability of conversion at a 20% discount to the per share price of a Funding Transaction	95%

Prior to the conversion into units on March 18, 2021, the fair value of the embedded derivative for the First and Second Note was determined to be \$1,627,881 using the Black-Scholes Option Pricing model with the following assumptions:

Risk-free interest rate	0.03% - 0.16%
Dividend yield	-
Expected life	0.61-3.00 years
Volatility	125% - 141%
Probability of automatic conversion	2.5%
Probability of conversion at \$1.60 per share	2.5%
Probability of conversion at a 20% discount to the per share price of a Funding Transaction	95%

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 6 – CONVERTIBLE DEBENTURES AND DERIVATIVE LIABILITY (continued)

During the three months ended March 31, 2021, the Company recognized interest expense of \$1,733 (2020 – \$nil) to third party lenders and \$3,796 (2020 – \$nil) to various directors and officers of the Company.

During the three months ended March 31, 2021, the Company recognized accretion of the debt discount of \$376,633 (2020 - \$nil) and gain on revaluation of derivative liability of \$23,950 (2020 – \$nil).

As at March 31, 2021, the principal and accrued interest balance owing to third party lenders was \$nil (December 31, 2020 - \$491,984) and the principal and accrued interest balance owing to various directors and officers of the Company was \$3,593,222 (December 31, 2020 - \$nil).

NOTE 7 – PROMISSORY NOTE

The following is a continuity schedule of the carrying value of the promissory notes and accrued interest:

	Principal	Accrued Interest
	\$	\$
Balance, December 31, 2019	855,062	2,313
Interest payments	-	(24,000)
Accretion	102,837	-
Accrued interest	-	24,229
Balance, December 31, 2020	957,899	2,542
Interest payments	-	(6,000)
Accretion	27,561	-
Accrued interest	-	5,974
Balance, March 31, 2021	985,460	2,516
Current portion	24,000	2,516
Long-term portion	961,460	-

In March 2015, the Company issued a promissory note of \$1,400,000 to Neurodyn Life Sciences Inc (“NLS”), a former related party through common shareholders, for the acquisition of the Alpha-1062 Technology (“NLS Promissory Note”) (Note 11). The NLS Promissory Note bore an interest rate of 6% and had a term of 2 years with no fixed repayment schedule. The Company may pay all or any portion of the note and accrued interest prior to the maturity date. The NLS Promissory Note was issued as a discount of \$214,367, which will be amortized over the term of the note at an effective interest rate of 15%.

In April 2015, the Company and NLS entered into an amendment to the License Agreement (defined in Note 11) pursuant to which the interest rate was reduced to 2% and the maturity date was extended to December 31, 2022 with interest only payments commencing April 1, 2019 at the rate of \$2,000 per month. The Company may pay all or any portion of the note and accrued interest prior to the maturity date.

In March 2019, the Company issued 600,000 Common Shares at a price of \$0.50 per share for a total value of \$300,000 as prepayment on the NLS Promissory Note for all interest outstanding and a portion of the principal amount. The prepayment was determined to be an extinguishment transaction with a related party which was in essence a capital transaction. As a result, the resulting difference of \$116,161 in net present value of the cash flows was recognized in the consolidated statement of changes in equity (deficiency) during the year ended December 31, 2019.

During the three months ended March 31, 2021, the Company recorded interest expense of \$5,974 (2020 - \$5,974) and amortization of the discount of \$27,561 (2020 - \$24,286) which is included in accretion expense.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 7 – PROMISSORY NOTE (continued)

As at March 31, 2021, the principal balance owing on the promissory note was \$1,211,463 (December 31, 2020 - \$1,211,463) and the remaining debt discount was \$226,003 (December 31, 2020 – \$253,564)

NOTE 8 – SHARE CAPITAL

Authorized share capital

During the three months ended March 31, 2021, the Company amended its articles to include additional classes of shares to its authorized share capital. As at March 31, 2021, the Company is authorized to issue the following share capital:

- Unlimited common voting shares without par value (“Common share”)
- Unlimited Class A restricted voting shares without par value (“Restricted share”)
- Unlimited Class B preferred Series A shares without par value (“Class B preferred shares”)

During the three months ended March 31, 2021, the Company completed a share consolidation on the basis of one new post-consolidation common share for every seven and fourteenths pre-consolidation common shares. All current and comparative references to the number of common shares, weighted average number of common shares, loss per share, stock options and warrants have been restated to give effect to this share consolidation.

Issued share capital

During the three months ended March 31, 2021, the Company issued the following shares:

- Concurrent to the Transaction, ACI Canada and ACI completed a brokered private placement by raising \$4,166,639 by way of the sale of 3,360,124 subscription receipts at a price of CAD\$1.60 per subscription receipt (“Subscription Receipt”) with each Subscription Receipt consisting of one common share and one-half warrant (“Private Placement”). Each whole warrant is exercisable at a price of CAD\$2.10 per warrant for a term of 24 months from the closing date. Of the funds raised, \$3,410,977 was raised by ACI Canada for 2,771,749 Subscription Receipts and \$755,662 was raised by ACI for 588,375 Subscription Receipts. In connection with the Private Placement, ACI Canada agreed to pay a cash commission of \$209,174 and issue 130,733 warrants under the Private Placement to the agents. Each agent warrant is exercisable into common shares of ACI at an exercise price of CAD\$1.60 for a term of 2 years.
- Concurrent to the Transaction, ACI Canada issued 1,613,186 Subscription Receipts on the conversion of \$2,296,019 worth of net convertible debentures (Note 6).
- Concurrent to the Transaction, ACI Canada issued 2,139,763 Common shares on the conversion of \$1,880,398 worth of net convertible debentures and 94,273 Common shares on the conversion of \$90,735 worth of interest on the convertible debentures (Note 6)

During the year ended December 31, 2020, the Company issued the following shares:

- 100,000 Common shares at a price of \$0.01 per share for total proceeds of \$1,000 for the exercise of Common share options. As a result, the Company transferred \$115,737 from reserves to share capital; and
- 2,480,334 Common shares for the conversion of 2,480,334 Class B common shares.

Warrants

During the three months ended March 31, 2021, ACI Canada issued the following warrants:

- 1,385,875 warrants with an exercise price of CAD\$2.10 and an expiry of March 18, 2023, in connection with the Company’s private placement.
- 130,733 warrants with an exercise price of CAD\$1.60 and an expiry of March 18, 2023, to the agents of the Company’s Private Placement. These warrants were valued at
- 806,591 warrants with an exercise price of CAD\$2.10 and an expiry of March 18, 2023, in connection with the conversion of the convertible debentures into Subscription Receipts.

All warrants outstanding in ACI Canada were transferred and assigned to ACI upon completion of the Transaction.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 8 – SHARE CAPITAL (continued)

Warrants (continued)

During the three months ended March 31, 2021, the Company issued 294,187 warrants with an exercise price of CAD\$2.10 and an expiry of March 18, 2023, in connection with the conversion of the convertible debentures into Subscription Receipts.

A summary of the Common share warrant transactions are summarized as follows:

	Number of Warrants	Weighted Average Exercise Price
Balance, December 31, 2019 and 2020	9,201,783	\$ 0.40
Issued	2,617,386	1.65 (CAD\$2.08)
Balance, March 31, 2021	11,819,169	0.67

A summary of the Common share warrants outstanding and exercisable at March 31, 2021, is as follows:

Warrants Outstanding	Exercise Price	Expiry Date
	\$	
440,000	0.40	July 5, 2023
8,761,783	0.40	August 30, 2024
2,486,653	1.67 (CAD\$2.10)	March 18, 2023
130,733	1.27 (CAD\$1.60)	March 18, 2023
11,819,169		

The weighted average life of warrants outstanding at March 31, 2021 was 5.54 years.

Share options

Common share options

The Company has a Stock Option Plan for its directors, officers, employees and consultants under which the Board of Directors of the Company may grant non-transferable share options totaling in aggregate up to 10% of the Company's issued and outstanding common shares, exercisable for a period of up to ten years from the date of grant, and at an exercise price which is not less than that permitted by the TSX-V.

All stock options outstanding in ACI Canada were transferred and assigned to ACI upon completion of the Transaction.

During the year ended December 31, 2020, the Company had the following share option transactions:

- On June 30, 2020, the Company's directors elected to convert all 900,000 outstanding Class B Common share options to Common share options on the same terms and conditions as originally issued on a 1:1 basis. The Class B Common share option plan was cancelled.
- During the year ended December 31, 2020, the Company granted 39,154 Common share options to a consultant of the Company with an estimated fair value of \$44,194 which vested immediately. Additionally, the Company cancelled 300,000 common shares.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 8 – SHARE CAPITAL (continued)

Share options (continued)

Common share options (continued)

During the year ended December 31, 2021, the Company had the following share option transactions:

- In connection with the Transaction, the Company granted 108,543 share options, with a total value of \$119,116, to former option holders of ACI of which all have been vested. The total fair value granted was considered to be part of the cost of acquisition of ACI. Of these stock options 31,513 are exercisable up to September 21, 2023, and 77,030 were exercisable up to June 16, 2021. In April 2021, the Company extended the life of the 77,030 share options to March 18, 2022.
- The Company granted 200,000 common share options to a consultant of the Company with an estimated fair value of \$145,920 which 50,000 vest quarterly commencing March 31, 2021.

The following weighted average assumptions were used in the Black-Scholes option-pricing model for the valuation of the share options issued:

	March 31, 2021	December 31, 2020
Risk-free interest rate	0.23%	0.60%
Dividend yield	-	-
Expected life	1.95 years	10 years
Volatility	125%	139%
Weighted average fair value per option	\$1.00	\$1.14

For the three months ended March 31, 2021, share-based compensation expense relating to service condition awards amounted to \$49,595 (three months ended March 31, 2020 - \$nil).

Common share option transactions are summarized as follows:

	Three months ended March 31, 2021		Year ended December 31, 2020	
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price
Balance, beginning of year	78,308	\$ 0.40	39,154	\$ 0.40
Granted	308,543	1.28	39,154	0.40
Balance, end of period	386,851	1.10	78,308	0.40
Options exercisable, end of period	236,851		78,308	

ALPHA COGNITION INC.
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (Expressed in United States Dollars)
 For the three months ended March 31, 2021 and 2020

NOTE 8 – SHARE CAPITAL (continued)

Share options (continued)

Common share options (continued)

A summary of the common share options outstanding at March 31, 2021, is as follows:

Options Outstanding	Options Exercisable	Exercise Price \$	Expiry Date
77,030	77,030	0.57 (CAD\$0.714)	June 16, 2021
200,000	50,000	1.67 (CAD\$2.10)	March 29, 2023
31,513	31,513	0.57 (CAD\$0.714)	September 21, 2023
39,154	39,154	0.40	June 1, 2029
39,154	39,154	0.40	July 22, 2030
386,851	236,851		

The weighted average life of common share options outstanding at March 31, 2021, was 3.05 years.

ACI Canada legacy performance options

The Company retained ACI Canada’s stock option plan whereby ACI Canada could grant stock options to directors, officers, employees and consultants enabling them to acquire common shares. Options granted had a maximum term of ten years and the board of directors determined the vesting requirements. From time to time, the Company granted performance-based share options to management and consultants. These options vest based on the Company’s achievement of certain performance goals and operational metrics, as applicable, subject to continuous employment by each recipient.

During the year ended December 31, 2020, the Company had the following ACI Canada legacy performance option transactions:

- On June 30, 2020, the Company’s directors elected to convert all 900,000 outstanding Class B common share options to common share options, subsequently included in the ACI Canada legacy performance option pool, on the same terms and conditions as originally issued on a 1:1 basis. The Class B common share option plan was cancelled.
- During the year ended December 31, 2020, the Company cancelled 300,000 common shares.

For the three months ended March 31, 2021, share-based compensation expense relating to service condition awards for the ACI Canada legacy performance options amounted to \$31,812 (three months ended March 31, 2020 - \$170,709).

For the three months ended March 31, 2021, share-based compensation expense relating to performance condition options for the ACI Canada legacy performance options amounted to \$562,391 (three months ended March 31, 2020 – \$107,593).

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 8 – SHARE CAPITAL (continued)

Share options (continued)

ACI Canada legacy performance options (continued)

ACI Canada legacy performance option transactions are summarized as follows:

	Three months ended March 31, 2021		Year ended December 31, 2020	
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price
		\$		\$
Balance, beginning of year	9,991,057	0.01	9,491,057	0.01
Converted from Class B Common share options	-	-	900,000	0.001
Exercised	-	-	(100,000)	0.01
Cancelled	-	-	(300,000)	0.01
Balance, end of period	9,991,057	0.01	9,991,057	0.01
Options exercisable, end of period	7,411,057		6,123,557	

A summary of the Common share options outstanding at March 31, 2021, is as follows:

Options Outstanding	Options Exercisable	Exercise Price	Expiry Date
		\$	
900,000	900,000	0.001	February 1, 2026
691,057	691,057	0.01	December 31, 2027
4,600,000	3,040,000	0.01	September 1, 2028
3,800,000	2,780,000	0.01	June 1, 2029
9,991,057	7,411,057		

The weighted average life of Common share options outstanding at March 31, 2021, was 7.44 years.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 8 – SHARE CAPITAL (continued)

Derivative liability

Due to the Company acquiring warrants from ACI Canada on the completion of the Transaction with an exercise price in a currency different from its functional currency, a derivative liability occurs on the date of the transfer of ACI Canada's previously issued warrants with USD exercise prices. This derivative liability is being revalued at each reporting period.

On initial recognition, the Company recorded a loss of \$10,488,499 to set up the derivative liability. As at March 31, 2021, the Company revalued the derivative liability to \$7,923,603 and recorded a gain of \$2,564,896.

A summary of the warrants with USD exercise prices outstanding and exercisable at March 31, 2021, is as follows:

Warrants Outstanding	Exercise Price	Expiry Date
	\$	
440,000	0.40	July 5, 2023
8,761,783	0.40	August 30, 2024
9,201,783		

The following weighted average assumptions were used in the Black-Scholes option-pricing model for the initial valuation and the valuation of the derivative liability as at March 31, 2021:

	March 31, 2021
Risk-free interest rate	0.48%
Dividend yield	-
Expected life	3.38 years
Volatility	113%
Weighted average fair value per warrant	\$1.57

NOTE 9 – RESEARCH AND DEVELOPMENT

The Company's research and development expenses are summarized below:

		For the three months ended March 31,	
	Note	2021	2020
		\$	\$
Consulting fees		209,031	295,616
Legal and patent costs		60,648	31,510
Management fees	9	203,102	105,000
Other research and development		9,466	22,039
Product development (recovery)		489,150	163,719
Share-based compensation	9	498,351	208,507
Salaries and benefits		152,430	-
		1,622,178	826,391

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 10 – RELATED PARTY TRANSACTIONS AND BALANCES

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company’s executive officers and members if it’s Board of Directors.

Summary of key management personnel compensation:

	For the three months ended March 31,	
	2021	2020
	\$	\$
Other general and administrative	9,000	13,500
Management fees	108,801	54,000
Professional fees	3,336	300
Research and development - management fees	113,333	105,000
Share-based compensation	590,316	177,142
	824,786	349,942

Amounts due to related parties are unsecured, non-interest bearing and have no specific terms of repayment. Below is a summary of related party balances:

	March 31, 2021	December 31, 2020
	\$	\$
Related parties payable		
Due to NLS	-	9,000
Accrued interest - NLS Promissory Note (Note 7)	-	2,542
Directors and officers	4,940	-
	4,940	11,542

A summary of related party convertible debentures transactions is included in Note 6. A summary of the promissory note held by a former related party is included in Note 7.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 11 – COMMITMENTS

a) Alpha-1062 Technology

In March 2015, the Company entered into the Memogain Technology License Agreement (“License Agreement”) with NLS for the exclusive right and license to further develop and exploit the Alpha 1062, formerly Memogain, Technology. The License Agreement set out the consideration as follows:

- The Company assumed all of NLS’s obligations under the Memogain Asset Purchase Agreement which consisted of cumulative total payments to Galantos Pharma GmbH of €10,000,000, the cumulative total may be increased to €15,000,000 subject to certain provisions, which is to be paid as follows (collectively the “Galantos Royalty Payments”):
 - 3% of the net sales revenue received by the Company from the sale of any products relating to the Alpha-1062 Technology;
 - 10% of any sublicensing revenue; and
 - 25% of an upfront payment or milestone payment paid by a sub-licensee to the Company;
- Upon completion of the Galantos Royalty Payments, a royalty payment to NLS of 1% of the revenue received from the Alpha-1062 Technology by the Company over \$100 million per annum and
- The issuance of a promissory note of \$1,400,000 to NLS (Note 7).

On January 1, 2016, the Company assumed NLS’s obligations under a Royalty Agreement with Galantos Consulting dated August 31, 2013, which consisted of cumulative total payments to Galantos Consulting of €2,000,000, the cumulative total may be increased to €3,000,000 subject to certain provisions, which is to be paid as follows:

- 1% of the net sales revenue received by the Company from the sale of any products relating to the Alpha-1062 Technology;
- 2% of any sublicensing revenue; and
- 2% of an upfront payment or milestone payment paid by a sub-licensee to the Company.

b) Alpha-602 Technology

In November 2020, the Company entered into a license agreement with NLS for the world-wide exclusive right to the Progranulin (“Alpha-602”) Technology. In accordance with the agreement, the Company will pay the following:

- \$50,000 to NLS before January 15, 2021 (paid);
- a royalty of 1.5% of the commercial sales, capped at \$2,000,000, to NLS;
- 10% of any Upfront Payments in excess of \$2,000,000.

The total amount payable to NLS under this agreement shall not exceed \$2,000,000.

NOTE 12 – CAPITAL DISCLOSURE AND MANAGEMENT

The Company defines its capital as all components of shareholders’ equity. The Company’s objective when managing capital is to safeguard the Company’s ability to continue as a going concern. The Company manages its capital structure to maximize its financial flexibility making adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets and business opportunities. The Company does not presently utilize any quantitative measures to monitor its capital. The Company is not subject to externally imposed capital requirements.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 13 – FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumption that market participants would use in pricing.

The Company's financial instruments consist of cash, subscription receipts receivable, accounts payable, related parties payable, convertible debentures, derivative liability, and promissory note. The fair values of subscription receipts receivable, accounts payable, related parties payable, refundable subscription receipts, convertible debentures and promissory note approximates their carrying values either due to their nature or current market rates for similar instruments. Cash is measured at fair value on a recurring basis using level 1 inputs. Derivative liability is measured at fair value on a recurring basis using level 3 inputs. The continuity and valuation techniques that are used to determine the fair value of the derivative liability are described in Notes 6 and 8.

The Company is exposed to a variety of financial risks by virtue of its activities including currency, credit, interest rate, and liquidity risk.

a) Currency risk

Foreign currency exchange rate risk is the risk that the fair value or future cash flows will fluctuate as a result of changes in foreign exchange rates. The Company's operations are carried out in Canada and the United States. As at March 31, 2021, the Company had net monetary assets of approximately \$3,100,000 denominated in Canadian dollars. These factors expose the Company to foreign currency exchange rate risk, which could have an adverse effect on the profitability of the Company. A 10% change in the exchange rate with the Canadian dollar would change net loss and comprehensive loss by approximately \$250,000. At this time, the Company currently does not have plans to enter into foreign currency future contracts to mitigate this risk, however it may do so in the future.

b) Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

The Company's cash is held in a large Canadian financial institution and a United States of America based financial institution. The Company maintains certain cash deposits with Schedule I financial institutions, which from time to time may exceed federally insured limits. The Company has not experienced any significant credit losses and believes it is not exposed to any significant credit risk. The Company's maximum credit risk is equal to the carrying value of cash at March 31, 2021 and December 31, 2020.

c) Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to interest rate cash flow risk. The Company does not hold any financial liabilities with variable interest rates. Financial assets and liabilities with fixed interest rates expose the Company to interest rate price risk. As at March 31, 2021, the promissory note bears interest of 2% per annum and is subject to interest rate price risk. The Company maintains bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk.

ALPHA COGNITION INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States Dollars)
For the three months ended March 31, 2021 and 2020

NOTE 13 – FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

d) Liquidity risk

The Company’s ability to continue as a going concern is dependent on management’s ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.

Contractual undiscounted cash flow requirements for financial liabilities as at March 31, 2021 are as follows:

	<1 Year	2-3 Years	Total
	\$	\$	\$
Accounts payable and accrued liabilities	614,029	-	614,029
Related parties payable	4,940	-	4,940
Promissory note	24,000	1,187,463	1,211,463
	642,969	1,187,463	1,830,432

NOTE 14 – SUPPLEMENTAL DISCLOSURES WITH RESPECT TO CASH FLOWS

	For the three months ended March 31,	
	2021	2020
Supplemental non-cash disclosures	\$	\$
Shares issued for funds previously received	1,898,740	-
Shares issued for conversion of convertible debentures and interest	4,267,152	-

NOTE 15 – SEGMENTED INFORMATION

The Company currently operates in a single reportable operating segment, being the researching and developing pharmaceutical treatments for neurological diseases. Geographic information is as follows:

	As at March 31, 2021		
	Canada	United States of America	Total
	\$	\$	\$
Non-current assets other than financial instruments	784,658	4,469	789,127

	As at December 31, 2020		
	Canada	United States of America	Total
	\$	\$	\$
Non-current assets other than financial instruments	732,247	3,727	735,974